Swiss Pharma CEO Warns Trump's Tariffs Threaten Patient Access
· anime
Tariffs Threaten Life-Saving Generics, Not Big Pharma’s Bottom Line
Richard Saynor, CEO of Sandoz, recently warned that “patients pay the tariff.” This stark reminder comes as President Trump considers imposing tariffs on generic drugs. The implications are far-reaching and disturbing: these tariffs would harm patients who rely on life-saving medications and undermine the US healthcare system.
Generic medicines have revolutionized treatment options for millions by making life-saving therapies more affordable. Ninety percent of prescriptions in the US are for generics and biosimilars, which is why Trump’s proposed tariffs are so alarming. Manufacturers like Sandoz would be forced to raise prices or stop supplying certain medications altogether. Saynor’s warning is not an empty threat but a cold calculation based on business realities.
The administration’s push for tariffs on imported generic medicines is often framed as a way to promote domestic pharmaceutical manufacturing. However, this line of thinking overlooks the fact that generics are already exempt from Section 232 pharmaceutical tariffs. Trump’s move would essentially be a tax hike on patients, with manufacturers serving only as middlemen.
Big Pharma companies like Novartis and Pfizer have spent years developing expensive brand-name drugs, which benefit from exclusive patent protection and allow them to charge high prices without direct competition for a limited period. In contrast, generic manufacturers like Sandoz enter the market after patents expire, competing on price, efficiency, and scale.
Generic medicines account for only a small share of overall US drug spending due to their lower prices. However, they are crucial in keeping healthcare costs manageable. The loss of access to these essential medications would harm patients and have far-reaching consequences for the entire healthcare system.
Sandoz plans to capitalize on what it sees as an unprecedented wave of patent expirations and exclusivity losses for branded medicines. The company aims to more than double its net sales by 2035 and increase its core profit margin to above 30%. This aggressive strategy is not surprising given the lucrative market opportunity ahead.
The multibillion-dollar potential in biosimilars, a highly similar alternative to complex biologic medicines, is particularly attractive. Saynor sees fewer competitors in this space due to the technical expertise required to produce these complex medications. With around 80% of the value of biologic drugs losing patent protection from 2035, Sandoz plans to target this vast market.
The recent split of Sandoz from Novartis highlights the growing importance of generic and biosimilar medicines in the US market. As a standalone company, Sandoz is well-positioned to capitalize on emerging opportunities. Its ambitious targets for net sales and profit margins reflect the enormous potential in this space.
Saynor’s warning serves as a stark reminder that Trump’s tariffs would harm patients and undermine the entire healthcare system. The proposed tax hike on generic medicines would drive up prices, reduce access to life-saving treatments, and exacerbate the already strained US healthcare budget. As the market continues to shift towards generics and biosimilars, it is imperative for policymakers to prioritize patient needs over corporate interests.
Reader Views
- MPMira P. · comics critic
The elephant in the room remains: how would manufacturers like Sandoz mitigate the impact of tariffs on their global supply chains? With operations spanning multiple countries, a US tariff hike could have far-reaching effects, from delayed shipments to production disruptions. If generics become too expensive or unreliable, patients will suffer, but so will the reputation of these very same companies that Trump claims want to "make America great again" by protecting domestic industries.
- TIThe Ink Desk · editorial
The proposed tariffs on generic drugs are a thinly veiled attempt by Big Pharma to protect their brand-name cash cows. But in reality, generics aren't the low-cost villains of the pharmaceutical world – they're the crucial lifeblood that keeps healthcare costs manageable. What's often overlooked is that generic manufacturers like Sandoz have already invested heavily in US-based manufacturing and research, so these tariffs would essentially be a tax on innovation itself.
- KAKenji A. · longtime fan
One aspect of this tariff proposal that's been overlooked is its potential impact on small US-based generic manufacturers, which often rely on imported active pharmaceutical ingredients (APIs) to produce their medications. If these companies can't afford the tariffs, they may be forced to consolidate with larger players or go out of business altogether, reducing competition and driving up prices even further for consumers. The administration needs to consider this unintended consequence when weighing its options.